Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Koshkin, Vasilij ^a   Krylov, Sergey N ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER;

ARTICLE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL POPULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; MICHAELIS MENTEN KINETICS; MULTIDRUG RESISTANCE; PROTEIN FUNCTION; PROTEIN TRANSPORT; TRANSPORT KINETICS;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYTOSTATIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS;

EID: 84864355632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041368     Document Type: Article

References (46)

1. Boumendjel A, Bouttonat J, Robert J, eds. (2009) ABC transporters and multidrug resistance. Hoboken, NJ.: John Wiley & Sons Eds. (.
2. Wartenberg M, Fischer K, Heschele J, Sauer H, (2002) Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta 1589: 49-62.
3. Shah MA, Schwartz GK, (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181.
4. Zhang W, Ling V, (2000) Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 184: 17-26.
5. Ramachandran C, Mead D, Wellham LL, Sauerteig A, Krishan A, (1995) Expression of drug resistance-associated mdr-1, GST pi, and topoisomerase II genes during cell cycle traverse. Biochem Pharmacol 49: 545-552.
6. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, et al. (1995) Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9: 799-807.
7. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
8. Schwab R, Micsik T, Szokoloczi O, Schafer E, Tihanyi B, et al. (2007) Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. Assay Drug Dev Technol 5: 541-550.
9. Koshkin V, Krylov SN, (2011) Single-cell-kinetics approach to compare multidrug resistance-associated membrane transport in subpopulations of cells. Anal Chem 83: 6132-6134.
10. Bidwell GL, 3rd, Raucher D (2006) Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 71: 248-256.
11. Zuo KQ, Zhang XP, Zou J, Li D, Lv ZW, (2010) Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res 38: 1428-1435.
12. Krylov SN, Zhang Z, Chan NW, Arriaga E, Palcic MM, et al. (1999) Correlating cell cycle with metabolism in single cells: combination of image and metabolic cytometry. Cytometry 37: 14-20.
13. Bauer TW, Tubbs RR, Edinger MG, Suit PF, Gephardt GN, et al. (1990) A prospective comparison of DNA quantitation by image and flow cytometry. Am J Clin Pathol 93: 322-326.
14. Claud RD, 3rd, Weinstein RS, Howeedy A, Straus AK, Coon JS (1989) Comparison of image analysis of imprints with flow cytometry for DNA analysis of solid tumors. Mod Pathol 2: 463-467.
15. Duggleby RG, (1995) Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 249: 61-90.
16. Stein RL, Barbosa MD, Bruckner R, (2000) Kinetic and mechanistic studies of signal peptidase I from Escherichia coli. Biochemistry 39: 7973-7983.
17. Cnubben NH, Wortelboer HM, van Zanden JJ, Rietjens IM, van Bladeren PJ, (2005) Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance. Expert Opin Drug Metab Toxicol 1: 219-232.
18. Haimeur A, Conseil G, Deeley RG, Cole SP, (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53.
19. Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, et al. (2001) Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun 284: 863-869.
20. Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, et al. (2009) Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 26: 914-925.
21. Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, et al. (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568.
22. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH, (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158.
23. Bernaudin JF, Fajac A, Fleury-Feith J, Kerrou K, Lacave R, (2009) ABC Proteins and Oncology: Expression, Detection, and Implication of ABC Proteins in Solid Tumors. In: Boumendjel A, Boutonnat J, Robert J, editors. pp. 143-176 editors. ABC transporters and Multidrug Resistance. Hoboken, NJ.: John Wiley&Sons, Inc.
24. Prosperi E, Croce AC, Bottiroli G, Supino R, (1986) Flow cytometric analysis of membrane permeability properties influencing intracellular accumulation and efflux of fluorescein. Cytometry 7: 70-75.
25. Saengkhae C, Loetchutinat C, Garnier-Suillerot A, (2003) Kinetic analysis of fluorescein and dihydrofluorescein effluxes in tumour cells expressing the multidrug resistance protein, MRP1. Biochem Pharmacol 65: 969-977.
26. Essodaigui M, Broxterman HJ, Garnier-Suillerot A, (1998) Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37: 2243-2250.
27. Lechner C, Reichel V, Moenning U, Reichel A, Fricker G, (2010) Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles. Eur J Pharm Biopharm 75: 284-290.
28. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A, (1998) Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 53: 141-147.
29. Saengkhae C, Loetchutinat C, Garnier-Suillerot A, (2003) Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1). Biophys J 85, 2006-2014.
30. Altschuler SJ, Wu LF, (2010) Cellular heterogeneity: do differences make a difference? Cell 141: 559-563.
31. Wong WW, Tsai TY, Liao JC, (2007) Single-cell zeroth-order protein degradation enhances the robustness of synthetic oscillator. Mol Syst Biol 3: 130.
32. Moreno-Otero R, Rodriguez S, Carbo J, Mearin F, Pajares JM, (1987) Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma. J Surg Oncol 36: 130-133.
33. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH, (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 5761-5766.
34. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, et al. (2008) Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98: 1515-1524.
35. Calcagno AM, Ambudkar SV, (2010) Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 596: 77-93.
36. Brauer MJ, Huttenhower C, Airoldi EM, Rosenstein R, Matese JC, et al. (2008) Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol Biol Cell 19: 352-367.
37. Sciuto R, Pasqualoni R, Bergomi S, Petrilli G, Vici P, et al. (2002) Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 43: 745-751.
38. Li J, Li ZN, Yu LC, Bao QL, Wu JR, et al. (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69: 116-122.
39. Langer R, Ott K, Feith M, Lordick F, Specht K, et al. (2010) High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 102: 503-508.
40. Krishan A, Bourguignon LY, (1984) Cell cycle related phenothiazine effects on adriamycin transport. Cell Biol Int Rep 8: 449-456.
41. Sunray M, Zurgil N, Shafran Y, Deutsch M, (2002) Determination of individual cell Michaelis-Menten constants. Cytometry 47: 8-16.
42. Eckford PD, Sharom FJ, (2008) Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47: 13686-13698.
43. Ninomiya M, Ito K, Horie T, (2005) Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab Dispos 33: 225-232.
44. Mao QQ, Bai Y, Lin YW, Zheng XY, Qin J, et al. (2010) Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res 54: 1574-1584.
45. Judson PL, Watson JM, Gehrig PA, Fowler WC Jr, Haskill JS, (1999) Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 59: 2425-2432.
46. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, et al. (2009) Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology 54: 657-666.